SpringerLink
Log in

Alzheimer-Medikamente: Phase-3-Studien

Alzheimerʼs drugs: phase 3 trials

  • Arzneimitteltherapie
  • Published:
DGNeurologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Dunn B, Stein P, Cavazzoni P (2021) Approval of aducanumab for alzheimer disease-the FDA’s perspective. JAMA Intern Med 181(10):1276–1278. https://doi.org/10.1001/jamainternmed.2021.4607

    Article  CAS  PubMed  Google Scholar 

  2. Insel PS et al (2020) ‘The A4 study: β‑amyloid and cognition in 4432 cognitively unimpaired adults. Ann Clin Transl Neurol 7(5):776–785. https://doi.org/10.1002/acn3.51048

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kivipelto M et al (2018) World wide fingers will advance dementia prevention. Lancet Neurol 17(1):27. https://doi.org/10.1016/S1474-4422(17)30431-3

    Article  PubMed  Google Scholar 

  4. Leuzy A et al (2021) Comparing the clinical utility and diagnostic performance of CSF P‑tau181, P‑tau217, and P‑tau231 assays. Neurology 97(17):e1681–e1694. https://doi.org/10.1212/WNL.0000000000012727

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mintun MA et al (2021) Donanemab in early alzheimer’s disease. N Engl J Med 384(18):1691–1704. https://doi.org/10.1056/NEJMoa2100708

    Article  CAS  PubMed  Google Scholar 

  6. Ngandu T et al (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385(9984):2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5

    Article  PubMed  Google Scholar 

  7. Nichols E et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7(2):e105–e125. https://doi.org/10.1016/S2468-2667(21)00249-8

    Article  Google Scholar 

  8. Novak P et al (2021) ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease. Nat Aging 1(6):521–534. https://doi.org/10.1038/s43587-021-00070-2

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Medizinische Fakultät, Heinrich-Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland

    C. Nelke

Authors
  1. C. Nelke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Nelke.

Ethics declarations

Interessenkonflikt

C. Nelke gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

F. Block, Schwerin

S. G. Meuth, Düsseldorf

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nelke, C. Alzheimer-Medikamente: Phase-3-Studien. DGNeurologie 5, 265–267 (2022). https://doi.org/10.1007/s42451-022-00439-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42451-022-00439-6

Search

Navigation